Sublobar Resection in the Treatment of Peripheral Typical Carcinoid Tumors of the Lung.


Journal

The Annals of thoracic surgery
ISSN: 1552-6259
Titre abrégé: Ann Thorac Surg
Pays: Netherlands
ID NLM: 15030100R

Informations de publication

Date de publication:
09 2019
Historique:
received: 15 08 2018
revised: 17 02 2019
accepted: 01 04 2019
pubmed: 7 5 2019
medline: 17 1 2020
entrez: 7 5 2019
Statut: ppublish

Résumé

The role of sublobar resection in the treatment of pulmonary typical carcinoids is controversial. This study aims to compare long-term outcomes between sublobar and lobar resections in patients with peripheral typical carcinoid. We retrospectively compared consecutive patients who underwent curative sublobar resection with patients who underwent lobectomy for cT1-3 N0 M0 peripheral pulmonary typical carcinoid in eight centers between 2000 and 2015. Primary outcomes were rates and patterns of recurrence and overall survival. Cox regression modeling was performed to identify factors influencing overall survival and recurrence. Propensity score analysis was done, and overall survival was compared between the two groups. In all, 177 patients were analyzed, consisting of 74 sublobar resections and 103 lobectomies, with a total of 857 person-years of follow-up. The R1 resection rates were 7% and 1% after sublobar resection and lobectomy, respectively (P = .08). One of 5 patients with sublobar R1 resection had recurrence. Recurrence rate was 0.02 (95% confidence interval [CI]: 0.009 to 0.044) per person-year of follow-up after sublobar resection and 0.008 (95% CI: 0.003 to 0.02) after lobectomy (P = .15). Five-year survival rates were 91.7% (95% CI: 78.5% to 96.9%) and 97.4% (95% CI: 90.1% to 99.4%) after sublobar and lobar resection, respectively (P = .08). Extent of resection was not a predictor of recurrence or survival. Propensity score analysis confirmed a similar survival and freedom from recurrence between the two groups. Sublobar resection of peripheral cT1-3 N0 M0 pulmonary typical carcinoid was not associated with worse short- or long-term outcomes compared with lobectomy. In select patients, sublobar resection may be considered for treatment of peripheral typical carcinoids if an R0 resection is obtained.

Sections du résumé

BACKGROUND
The role of sublobar resection in the treatment of pulmonary typical carcinoids is controversial. This study aims to compare long-term outcomes between sublobar and lobar resections in patients with peripheral typical carcinoid.
METHODS
We retrospectively compared consecutive patients who underwent curative sublobar resection with patients who underwent lobectomy for cT1-3 N0 M0 peripheral pulmonary typical carcinoid in eight centers between 2000 and 2015. Primary outcomes were rates and patterns of recurrence and overall survival. Cox regression modeling was performed to identify factors influencing overall survival and recurrence. Propensity score analysis was done, and overall survival was compared between the two groups.
RESULTS
In all, 177 patients were analyzed, consisting of 74 sublobar resections and 103 lobectomies, with a total of 857 person-years of follow-up. The R1 resection rates were 7% and 1% after sublobar resection and lobectomy, respectively (P = .08). One of 5 patients with sublobar R1 resection had recurrence. Recurrence rate was 0.02 (95% confidence interval [CI]: 0.009 to 0.044) per person-year of follow-up after sublobar resection and 0.008 (95% CI: 0.003 to 0.02) after lobectomy (P = .15). Five-year survival rates were 91.7% (95% CI: 78.5% to 96.9%) and 97.4% (95% CI: 90.1% to 99.4%) after sublobar and lobar resection, respectively (P = .08). Extent of resection was not a predictor of recurrence or survival. Propensity score analysis confirmed a similar survival and freedom from recurrence between the two groups.
CONCLUSIONS
Sublobar resection of peripheral cT1-3 N0 M0 pulmonary typical carcinoid was not associated with worse short- or long-term outcomes compared with lobectomy. In select patients, sublobar resection may be considered for treatment of peripheral typical carcinoids if an R0 resection is obtained.

Identifiants

pubmed: 31059684
pii: S0003-4975(19)30611-3
doi: 10.1016/j.athoracsur.2019.04.005
pii:
doi:

Types de publication

Comparative Study Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

859-865

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Informations de copyright

Copyright © 2019 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

Auteurs

Maria Cattoni (M)

Division of Thoracic Surgery, Swedish Cancer Institute, Seattle, Washington; Department of Medicine and Surgery, Center for Thoracic Surgery, University of Insubria, Varese, Italy.

Eric Vallières (E)

Division of Thoracic Surgery, Swedish Cancer Institute, Seattle, Washington.

Lisa M Brown (LM)

Department of Surgery, Section of General Thoracic Surgery, UC Davis Health, Sacramento, California.

Amir A Sarkeshik (AA)

Department of Surgery, Section of General Thoracic Surgery, UC Davis Health, Sacramento, California.

Stefano Margaritora (S)

Unit of Thoracic Surgery, Catholic University Sacred Heart, Rome, Italy.

Alessandra Siciliani (A)

Unit of Thoracic Surgery, Catholic University Sacred Heart, Rome, Italy.

Pier Luigi Filosso (PL)

Department of Thoracic Surgery, San Giovanni Battista Hospital, Torino, Italy.

Francesco Guerrera (F)

Department of Thoracic Surgery, San Giovanni Battista Hospital, Torino, Italy.

Andrea Imperatori (A)

Department of Medicine and Surgery, Center for Thoracic Surgery, University of Insubria, Varese, Italy.

Nicola Rotolo (N)

Department of Medicine and Surgery, Center for Thoracic Surgery, University of Insubria, Varese, Italy.

Farhood Farjah (F)

Department of Surgery, University of Washington Medical Center, Seattle, Washington.

Grace Wandell (G)

Department of Surgery, University of Washington Medical Center, Seattle, Washington.

Kimberly Costas (K)

Division of Thoracic Surgery, Providence Regional Medical Center, Everett, Washington.

Catherine Mann (C)

Division of Thoracic Surgery, Swedish Cancer Institute, Seattle, Washington.

Michal Hubka (M)

Division of Thoracic Surgery, Virginia Mason Hospital and Seattle Medical Center, Seattle, Washington.

Stephen Kaplan (S)

Division of Thoracic Surgery, Virginia Mason Hospital and Seattle Medical Center, Seattle, Washington.

Alexander S Farivar (AS)

Division of Thoracic Surgery, Swedish Cancer Institute, Seattle, Washington.

Ralph W Aye (RW)

Division of Thoracic Surgery, Swedish Cancer Institute, Seattle, Washington.

Brian E Louie (BE)

Division of Thoracic Surgery, Swedish Cancer Institute, Seattle, Washington. Electronic address: brian.louie@swedish.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH